14 matches for your search in the start-up spotlight
rss
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
18-Feb-2025
Infex Therapeutics, a leading anti-infectives specialist, announces that in collaboration with Justus-Liebig-University Giessen (“JLU”), Germany it has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), to develop a first-in-class BamA inhibitor targeting ...
Glox Therapeutics awarded share of £3M Collaborative Discovery Programme funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
28-Jan-2025
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) ...
Non-profit organization supports start-ups in the development of urgently needed new antibiotics
02-Jul-2024
INCATE, the INCubator for Antimicrobial Therapies in Europe, has been honoured with the 2024 Lighthouse Award for outstanding Transfer of Knowledge and Technology by the Swiss National Science Foundation (SNSF). The award ceremony took place on June 27th, in Bern, Switzerland. The SNSF has ...
Spin-off has built a platform that creates new ways to tackle bacterial infections
11-Dec-2023
Obulytix, a groundbreaking biotech spin-off founded by seasoned experts in phage lysin research from Ghent University and KU Leuven, is set to revolutionize the fight against antimicrobial resistance with its novel phage lysin-based antibiotics. The innovative, phage lysin-based platform – ...
An important step towards integrating precision medicine and antibiotic resistance control
07-Dec-2023
Lifespin GmbH, an emerging company in the field of precision health information, introduces its Therapeutic Drug Monitoring (TDM) of anti-infectives. This Laboratory Development Test (LDT) represents a significant advance in the field of personalized medicine by enabling individualized approaches ...
Spin-out from the Universities of Glasgow and Oxford
21-Nov-2023
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use ...
Smartbax nominated for Falling Walls award
06-Nov-2023
It all began with basic research: While conducting laboratory experiments, a team at the Technical University of Munich (TUM) came across an active agent against multidrug-resistant bacteria with a fundamental difference to antibiotics developed to date. The researchers have since established a ...
In minutes rather than days to prescribe the optimal antibiotic
13-Sep-2023
Glasgow diagnostics spinout Microplate Dx has closed a £2.5M seed funding round to develop its point-of-care diagnostic platform which can confirm the presence of bacteria and guide a patient’s doctor to effective treatment by rapidly identifying effective antibiotics to use and which ones to ...
A total of sixteen teams presented their innovative ideas to almost 50 investors at the Munich start-up center.
18-Jul-2023
On July 13, 2023, the Munich Innovation and Start-up Center for Biotechnology (IZB) organized the 8th Life Science Pitch Day in cooperation with High-Tech Gründerfonds (HTGF), Leaps by Bayer, and Boehringer Ingelheim, which brought together sixteen biotech start-ups and project teams and almost ...
SANTERO announces a €8 million Series A funding round led by Newton Biocapital
12-Jun-2023
Newton Biocapital (NBC), a venture capital firm focused on investing and growing early-stage life sciences companies in Europe and Japan targeting chronic health conditions, has announced the closing of a successful €8 million Series A financing round for Santero. SANTERO, a spin-off company of ...
